An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a midstage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of standard-of-care statin therapy, as compared with placebo. AZD0780 is an ...

Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT trial when added to standard statin therapy.

Upbeat Data From AZN’s Phase II Cholesterol Drug Study AstraZeneca presented positive data from a mid-stage study of its investigational once-daily oral PCSK9 inhibitor, AZD0780, at the annual ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol (LDL-C). It acts as a small molecule inhibitor of proprotein ...